Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ph2 ARX788 HER2 BC T-DMI T-DXd
View
Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph2 ARX788 HER2 BC T-DMI T-DXd
View
Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
Ph2 ARX788 HER2 BC T-DMI T-DXd
View
Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
Ph2 ARX788 HER2 BC T-DMI T-DXd
View
Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: II
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: I/II
Title:
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
View
Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: I/II
Title:
SCRI:BRE 405: Ph3 AZD9833 vs AI or Tamox HR+/HER2- BC (CAMBRIA-1)
View
Description: CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive LocoregionalTherapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (D8531C00002)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
SCRI:BRE 405: Ph3 AZD9833 vs AI or Tamox HR+/HER2- BC (CAMBRIA-1)
View
Description: CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive LocoregionalTherapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (D8531C00002)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
SCRI:BRE 405: Ph3 AZD9833 vs AI or Tamox HR+/HER2- BC (CAMBRIA-1)
View
Description: CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive LocoregionalTherapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (D8531C00002)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
SCRI:BRE 405: Ph3 AZD9833 vs AI or Tamox HR+/HER2- BC (CAMBRIA-1)
View
Description: CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive LocoregionalTherapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (D8531C00002)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)
View
Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)
View
Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I/II
Title:
Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)
View
Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I/II
Title:
Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)
View
Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: I/II
Title:
SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC
View
Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC
View
Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC
View
Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC
View
Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: II
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
View
Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Ryz101 for SSTR+ ER+HER2 metastatic breast cancer
View
Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1).(RYZ101-201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ryz101 for SSTR+ ER+HER2 metastatic breast cancer
View
Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1).(RYZ101-201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I/II
Title:
Ryz101 for SSTR+ ER+HER2 metastatic breast cancer
View
Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1).(RYZ101-201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I/II
Title:
Ryz101 for SSTR+ ER+HER2 metastatic breast cancer
View
Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1).(RYZ101-201)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: I/II
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III